대사 장애용 펩티드 치료제 시장 : 투여 경로별, 합성 기술별, 유통 채널별, 지역별

Peptide Therapeutics In Metabolic Disorders Market is estimated to be valued at USD 39.3 Bn in 2026 and is expected to reach USD 47.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.6% from 2026 to 2033.

Peptide therapeutics play an increasingly important role in treating metabolic disorders such as diabetes, obesity, and related conditions. These therapies target biological pathways that regulate glucose levels, appetite, insulin activity, and energy metabolism. Rising disease prevalence and demand for effective long-term treatments encourage pharmaceutical companies to advance peptide-based therapies. Meanwhile, improvements in peptide engineering, drug delivery, and formulation technologies help developers enhance treatment performance and expand the use of peptide therapeutics in metabolic disease management.

Pharmaceutical companies are developing next-generation peptide therapies that improve treatment effectiveness, durability, and patient convenience. Incretin-based therapies, including GLP-1 and dual- or multi-receptor agonists, have expanded the use of peptide medicines in metabolic care. Researchers are also advancing oral delivery systems, extended-release formulations, combination therapies, and novel molecular targets. These innovations are broadening treatment options and driving investment in clinical development, manufacturing capacity, and advanced peptide-based therapeutic platforms.

Market Dynamics

The rising prevalence of diabetes, obesity, and other metabolic disorders continues to increase demand for effective treatments. Healthcare providers seek therapies that support durable disease management and improve patient outcomes. Peptide therapeutics target specific metabolic pathways and continue to gain clinical interest. Pharmaceutical companies are expanding research programs and developing innovative peptide-based therapies to address unmet treatment needs across diabetes, obesity, and related metabolic conditions.

Advances in peptide engineering, molecular design, drug delivery, and formulation technologies are improving therapeutic performance and patient convenience. Developers are creating longer-acting formulations, oral delivery systems, combination therapies, and multi-target molecules to enhance treatment outcomes. The success of incretin-based therapies has encouraged pharmaceutical companies to investigate additional biological targets and treatment combinations. These innovations are expanding peptide applications and attracting greater investment across the development pipeline.

Pharmaceutical companies face several challenges when developing and manufacturing peptide therapeutics. Complex molecular structures, stability requirements, specialized production processes, and strict quality-control standards can increase development complexity. Developers must conduct extensive clinical studies to establish long-term safety and efficacy. Alternative treatment options and patient adherence concerns also influence competition. Companies that improve drug delivery, manufacturing efficiency, treatment duration, and patient convenience can strengthen their position in metabolic disorder treatment.

Key Features of the Study

• It highlights potential revenue opportunities across various market segments and provides attractive investment proposition matrices for stakeholders involved in the Peptide Therapeutics in Metabolic Disorders Market.
• This study offers key insights into market drivers, restraints, opportunities, emerging peptide technologies, drug delivery advancements, incretin-based therapies, therapeutic innovations, clinical development trends, regional outlook, and competitive strategies adopted by leading market participants.
• It profiles key players in the Peptide Therapeutics in Metabolic Disorders Market based on company overview, therapeutic portfolio, pipeline analysis, recent developments, clinical advancements, financial performance, and strategic initiatives.
• Key companies covered as part of this study include AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.
• Insights from this report enable pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, and management teams to make informed decisions regarding drug development, peptide innovation, clinical research, manufacturing investments, market expansion, strategic collaborations, and therapeutic commercialization.
• The Peptide Therapeutics in Metabolic Disorders Market report serves a wide range of stakeholders, including investors, pharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, healthcare providers, research institutions, technology developers, new market entrants, and financial analysts.
• Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, therapeutic pipeline assessment, treatment application analysis, regional evaluation, and market evaluation matrices presented in the Peptide Therapeutics in Metabolic Disorders Market report.

Market Segmentation

• By Route Of Administration (Revenue, USD Bn, 2021-2033)
  • Intravenous
  • Oral
  • Nasal
  • Others
• By Synthesis Technology (Revenue, USD Bn, 2021-2033)
  • Solid Phase Peptide Synthesis
  • Liquid Phase Peptide Synthesis
  • Hybrid Technology
• By Distribution Channels (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Specialty Clinics
  • Retail Pharmacy
  • Online Pharmacy
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • PolyPeptide Group
  • Eli Lilly and Company
  • Bachem Holding AG
  • Takeda Pharmaceuticals Co. Ltd.
  • Ipsen S.A
  • Rhythm Pharmaceuticals Inc.
  • Novo Nordisk A/S.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Synthesis Technology
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Peptide Therapeutics In Metabolic Disorders Market, By Route of Administration, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Peptide Therapeutics In Metabolic Disorders Market, By Synthesis Technology, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Solid Phase Peptide Synthesis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Liquid Phase Peptide Synthesis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Hybrid Technology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Peptide Therapeutics In Metabolic Disorders Market, By Distribution Channel, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Peptide Therapeutics In Metabolic Disorders Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • AstraZeneca plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • PolyPeptide Group
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bachem Holding AG
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Takeda Pharmaceuticals Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Ipsen S.A
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Rhythm Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Novo Nordisk A/S.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us